- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Helping Patients With Metastatic Breast Cancer Enroll in Clinical Trials
Sonya Negley, IOM, CSMA, describes the patient advocate’s role in helping patients with metastatic breast cancer discover and enroll in clinical trials.
EP: 1.Differences Between SERDs and Other Therapies
EP: 2.Efficacy of Oral SERDs in the EMERALD Trial
EP: 3.Safety Concerns Associated With Oral SERDs
EP: 4.Benefits of Using Oral SERDs
EP: 5.Progression-Free Survival of Oral SERDs in Clinical Practice
EP: 6.Role of Oral SERDs in Treatment of ER+/HER2- in Metastatic Breast Cancer
EP: 7.ESR1 Mutation Confirmation With Oral SERDs
EP: 8.Coverage Considerations for Oral SERDs
EP: 9.Clinical Impact of Oral SERDs
EP: 10.Treatment Failure and Resistance Before Oral SERDs
EP: 11.Cardiovascular Risk and Menopausal Symptoms Associated With Oral SERDs
EP: 12.Monitoring and Managing Adverse Effects With Oral SERDs
EP: 13.Payer Perspectives on SERDs
EP: 14.Ensuring Access to Oral SERDs
EP: 15.How Patient Advocates Can Help the Newly Diagnosed
EP: 16.Empowering Patients With Metastatic Breast Cancer
EP: 17.Helping Patients With Metastatic Breast Cancer Enroll in Clinical Trials
EP: 18.Guiding Patients Through Complex Treatment Decisions
EP: 19.Patient Advocate's Role in Shared Decision Making
EP: 20.Helping Patients Overcome Health Disparities as a Patient Advocate
Sonya Negley, IOM, CSMA: I think there are a few things we can do as organizations. We can make sure we are educating patients about what is available in clinical trials, and we as patient advocacy organizations need to look at it comprehensively, not just trials that may or may not be on clinicaltrials.gov, but clinical trials in general, and how can those trials support the patient? I think we have to be very cautious that it’s not the patient’s work to go out and make sure all of the trials have patients involved or that type of thing. But more so, giving their input in the way they feel they can best share their voice.
We want people who are living with metastatic breast cancer to feel like they are doing everything in their life that they want to do. Their lives are shortened, and it is incredibly important that they spend time with their loved ones. And it’s important for all of us to remember, whether we’re in research, science, or in patient advocacy, that people’s time that we’re using is time they’re taking away from their loved ones. So, [we need to] be efficient in making sure their goals are met, and [understanding] it’s a very important task, and [helping patients realize] that their participation is going to reward them personally, as well as rewarding discovery in this space.
Transcript edited for clarity.
Trastuzumab Biosimilar Gets Go Ahead in EU for HER2+ Breast and Metastatic Gastric Cancers
December 5th 2023EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union (EU) for the treatment of patients with HER2-positive (HER2+) breast and metastatic gastric cancer; these are the same indications that trastuzumab holds in the European Union.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
The FDA has approved capivasertib plus fulvestrant for the treatment of patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alteration, following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Read More
The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer
February 22nd 2022On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.
Listen
